Eventos adversos supuestamente atribuidos a vacunas contra la COVID-19 en pacientes atendidos por consultorio externo de Neumología en hospitales de la red Essalud- Piura, 2022.

Saved in:

Bibliographic Details
Title:	Eventos adversos supuestamente atribuidos a vacunas contra la COVID-19 en pacientes atendidos por consultorio externo de Neumología en hospitales de la red Essalud- Piura, 2022.
Alternate Title:	Adverse events supposedly attributed to COVID-19 vaccines in patients treated by Pulmonlogy outpatient service in hospitals of the Essalud-Piura network, 2022.
Authors:	Gabriel Farfán-Chávez, Luis¹ farfan_chavez_luis@hotmail.com, Wong, Guiovanna¹ ana.lamadrid@essalud.gob.pe, Pérez-Acuña Medina, Katherine Alexandra^2,3 katy_per@hotmail.com, Jennifer Torres-Robles, Ruby^4,5, Alberto Rodriguez-Saldaña, Christian¹, La-Madrid, Ana¹
Source:	Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo. Oct-Dec2025, Vol. 18 Issue 4, p1-18. 18p.
Subjects:	Drug side effects, COVID-19 vaccines, Outpatient medical care, Age factors in disease, Respiratory infections, Gender differences (Sociology), Health care networks, Pulmonology
Abstract (English):	Introduction: COVID-19 vaccines have been essential in controlling the pandemic, but concerns have arisen regarding their adverse effects. This study evaluates the incidence of adverse effects in vaccinated patients attending Pneumology outpatient clinics in the EsSalud Piura network in 2022. Methods: A cross-sectional study was conducted with 254 patients over 18 years of age who received at least one dose of a COVID-19 vaccine (Pfizer, Sinopharm, or AstraZeneca). Data were obtained through a review of medical records and structured interviews. Adverse effects were classified as local or systemic. Crude (RPc) and adjusted prevalence ratios (RPa) were calculated using Poisson models, adjusting for age, sex, comorbidities, and prior COVID-19 infection. Results: Most patients 60.6% were ≤60 years old, and 86.2% had comorbidities. RPa showed that respiratory infection sequelae significantly increased the risk of adverse effects after the third dose (RPa: 1.66; 95% CI: 1.17-2.35; p=0.004). Additionally, patients over 60 years and females were also associated with a higher likelihood of adverse effects (RPa: 1.29; 95% CI: 0.92-1.80 and RPa: 1.15; 95% CI: 0.83-1.60, respectively). Conclusion: COVID-19 vaccines, particularly the third dose, showed a higher incidence of adverse effects in patients with respiratory sequelae. Women and those over 60 years also had a higher risk of adverse effects. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Introducción: Las vacunas contra la COVID-19 han sido esenciales para controlar la pandemia, pero han generado preocupación por sus efectos adversos. Este estudio evalúa la incidencia de efectos adversos en pacientes vacunados atendidos en consultorios de Neumología en la red EsSalud Piura en 2022. Métodos: Se realizó un estudio transversal en 254 pacientes mayores de 18 años, quienes recibieron al menos una dosis de vacuna contra la COVID-19 (Pfizer, Sinopharm o AstraZeneca). Los datos fueron obtenidos mediante revisión de historias clínicas y entrevistas estructuradas. Los efectos adversos fueron clasificados como locales y sistémicos. Se calcularon las razones de prevalencia crudas (RPc) y ajustadas (RPa) utilizando modelos de Poisson, ajustando por edad, sexo, comorbilidades y antecedentes de COVID-19. Resultados: La mayoría de los pacientes 60.6% tenían ≤60 años y el 86.2% presentaba comorbilidades. Las RPa mostraron que las secuelas de infecciones respiratorias aumentaron significativamente el riesgo de efectos adversos tras la tercera dosis (RPa: 1.66; IC 95%: 1.17-2.35; p=0.004). Además, los pacientes mayores de 60 años y el sexo femenino también estuvieron asociados con una mayor probabilidad de efectos adversos (RPa: 1.29; IC 95%: 0.92-1.80 y RPa: 1.15; IC 95%: 0.83-1.60, respectivamente). Conclusión: Las vacunas contra la COVID-19, en especial la tercera dosis, mostraron una mayor incidencia de efectos adversos en pacientes con secuelas respiratorias. Las mujeres y los mayores de 60 años también presentaron mayor riesgo de efectos adversos. [ABSTRACT FROM AUTHOR]
	Copyright of Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo is the property of Cuerpo Medico del Hospital Nacional Almanzor Aguinaga Asenjo and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Introduction: COVID-19 vaccines have been essential in controlling the pandemic, but concerns have arisen regarding their adverse effects. This study evaluates the incidence of adverse effects in vaccinated patients attending Pneumology outpatient clinics in the EsSalud Piura network in 2022. Methods: A cross-sectional study was conducted with 254 patients over 18 years of age who received at least one dose of a COVID-19 vaccine (Pfizer, Sinopharm, or AstraZeneca). Data were obtained through a review of medical records and structured interviews. Adverse effects were classified as local or systemic. Crude (RPc) and adjusted prevalence ratios (RPa) were calculated using Poisson models, adjusting for age, sex, comorbidities, and prior COVID-19 infection. Results: Most patients 60.6% were ≤60 years old, and 86.2% had comorbidities. RPa showed that respiratory infection sequelae significantly increased the risk of adverse effects after the third dose (RPa: 1.66; 95% CI: 1.17-2.35; p=0.004). Additionally, patients over 60 years and females were also associated with a higher likelihood of adverse effects (RPa: 1.29; 95% CI: 0.92-1.80 and RPa: 1.15; 95% CI: 0.83-1.60, respectively). Conclusion: COVID-19 vaccines, particularly the third dose, showed a higher incidence of adverse effects in patients with respiratory sequelae. Women and those over 60 years also had a higher risk of adverse effects. [ABSTRACT FROM AUTHOR]
ISSN:	22255109